semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Stroke Obesity Overweight Hemiparesis Acute ischemic stroke within 30 days of randomization 2. Age 18-80 years 3. BMI 27-49.9 mg/kg2 4. New or worse unilateral upper extremity weakness attributable to index stroke 5. Score of 0-54 on the Fugl-Meyer upper extremity scale 6. Able to meet all nutritional and fluid needs by oral intake. 7. Ready to undergo behavioral change 8. Able and willing to sign document outlining importance of following the study protocol 9. Able and willing to provide written informed consent  Medical contraindication to weight loss or diet, including the following: renal disease requiring dialysis, taking lithium, or end stage liver or renal disease considered incompatible with diet intervention by patient's personal healthcare provider or the study PI 2. Enrollment in a conflicting clinical trial (defined as a trial with an intervention known to affect weight or with an for participation in another trial) 3. Pregnancy or desire to become pregnant, or currently breastfeeding 4. High-risk of malnutrition using a standard screen73 5. Trajectory of recent weight loss (i.e., loss of at least 12 lbs in the 3 months preceding screening) 6. Allergy to soy based food products 7. Inability to communicate with study team 8. Inability to speak English 9. Irreversible medical conditions likely to affect short-term survival (predicted survival of less than one year)
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Tuberculosis Tuberculosis, Pulmonary Cavity Bronchoscopy Acid Fast Bacilli Infection Multi-drug Resistant Tuberculosis Transmission Insolation A. Cavitary Pulmonary TB Group 1. Aged 18 years and older 2. The patient who has the cavitary pulmonary TB  Age < 18 years 2. Any Malignant patient 3. Patients with bacterial or viral or fungal pneumonia based on the judgment of the attending physician 4. Patients who had a history of any pulmonary cystic lesion such as infected bulla, bullous emphysema 5. Patients who were diagnosed with pulmonary fungal infection or previous its history or any documented culture of the fungus from a bronchial sample including sputum 6. Patients who were diagnosed with bronchiectasis 7. Patients who were diagnosed with NTM-PD (non-tuberculous mycobacterial pulmonary disease) or any documented culture of NTM from a bronchial sample including sputum 8. Patients who were diagnosed with connective tissue disease such as Wegener's granulomatosis, SLE 9. Patients who were diagnosed with TB destroyed lung 10. Patients who were diagnosed with congenital lung disease such as Congenital Cystic Adenomatoid Malformation (CCAM), pulmonary sequestration 11. Patients who were diagnosed with interstitial lung disease such as Lymphangioleiomyomatosis (LAM), idiopathic pulmonary fibrosis (IPF) 12. Patients who were diagnosed with culture-negative pulmonary TB 13. Patients who did not take anti-TB medication more than twice a week on average 14. Patients who were diagnosed with sarcoidosis 15. Patients who were diagnosed with paragonimiasis 16. Patients who were diagnosed with pulmonary thromboembolism due to excluding pulmonary infarction 17. The patient who did not consent 18. Patients who were diagnosed with MDR/XDR TB through AFB culture B. Endobronchial TB Group 1. Aged 18 years and older 2. The patient who has the endobronchial TB through bronchoscopy Age < 18 years 2. Patient who was not consented
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Multi-drug Resistant Tuberculosis Is willing and able to give informed consent to participate in the trial treatment and follow-up Is aged between 18 years and 70 years Has a positive sputum culture result or a positive GeneXpert result Has evidence of RR-TB or MDR-TB either by GeneXpert or culture-based drug susceptibility testing (DST) Non pre-XDR-TB or XDR-TB Is willing to use effective contraception of women at childbearing age Has had a chest X-ray that is compatible with a diagnosis of pulmonary TB  pre-XDR-TB or XDR-TB Has a known allergy to any drug of the regimen Is currently taking or took part in another trial less than three months before the study initiation  Is HIV positive Has abnormal ECG with QT prolongation over 430ms of men while 450 of women Is critically ill, and in the judgment of the investigator, unlikely to take part in the study.Or has any condition (social or medical) which in the opinion of the investigator would make study participation unsafe Is known to be pregnant or breast-feeding Has severe cardiovascular diseases, such as heart failure, hypertension (poor blood pressure control), arrhythmia or post-infarction status Has severe concomitant severe disease such as respiratory failure or cardiac insufficiency or liver and kidney injury with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 2.5 times the upper limit of normal or with serum creatinine(Cr)more than 1.3 times the upper limit of normal Has Karnofsky score less than 50%
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Renal Transplant Failure Participants with chronic renal failure scheduled for living-related kidney transplantation surgery  participants with severe left ventricular dysfunction cardiomyopathy with ejection fraction 50% severe anemia (blood hemoglobin Hb5g\ dL) bleeding tendency  previously received transplants experienced any surgical complications (e.g., excessive bleeding or resistant graft arterial spasm any surgical difficulty such as the presence of multiple renal vessels
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Pneumocystis HIV/AIDS Steroid Older than 18 years To have a gasometry at the admission that confirms moderate or severe PCP Patients receiving trimethoprim / sulfamethoxazole in doses of 15 to 20 mg / kg per day from the first 24 hours after admission Patients who have begun adjuvant treatment with steroids in the first 48 hours after admission No history of chronic pulmonary disease at hospitalization less than 20 points  Allergic to TMP/SMX, who have not tolerated desensitization History of inflammatory, infectious, autoimmune or neoplastic diseases except Kaposi's sarcoma, which merit the chronic use of steroids Pleural or pericardial effusion and meningitis from any cause Septic shock not related to PCP Subjects who during the hospitalization have been diagnosed with any neoplasia (except Kaposi´s sarcoma)
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acute Decompensated Heart Failure Diuretics Resistance Age more than 18 years Chronic heart failure prior diagnosis, based on signs and or symptoms of heart failure, presenting with acute decompensation as judged by the physician to require hospitalization for IV diuretics  Refusal to participate in the study Allergy to IV frusemide Severe renal impairment defined as eGFR<30ml/m Cardiogenic shock or hemodynamic instability judged by the treating physician to be unsuitable to participate
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Tuberculosis Adult age between 18 years and 55 years Body mass index (BMI) greater than 18.5 kg/m^2 At least 8 years formal education, with appropriate reading and comprehension skills Able and willing to provide written informed consent Males must agree to using contraception during the study and for 2 weeks after the last dose of study drug If a female participant is of reproductive potential, the participant (and her partner) must agree to use of one of the following combinations of birth control during the study and for 2 weeks after the last dose of study drug (or tubal ligation as a single method) Use of a double-barrier method of contraception: condoms (male or female) and a diaphragm or cervical cap with spermicide Use of an intrauterine device (IUD) and a barrier method: condoms (male or female, with or without spermicide) or a diaphragm or cervical cap with spermicide Tubal ligation Important Note: Due to documented effects of rifabutin on effectiveness of hormonal contraceptives (16-18), these are not included as options here with the exception of an IUD. Women who are post-menopausal, defined as age greater than 45 and no menses for at least 1 year, or who have had a hysterectomy, are considered not of reproductive potential  Current or imminent treatment for significant infection Pregnant or breastfeeding HIV positive status as determined by a U.S. Food and Drug Administration (FDA)-approved HIV assay Hepatitis B infection, as determined by an FDA-approved hepatitis B surface antigen assay Hepatitis C infection, as determined by an FDA-approved positive Hepatitis C antibody assay Known infection with Mycobacterium tuberculosis (MTB) History of allergy or hypersensitivity to imatinib, isoniazid or rifabutin History of enrollment in other clinical trials with investigational agents within 8 weeks Cardiac arrhythmia requiring medication, or any clinically significant electrocardiogram (ECG) abnormality Exam consistent with congestive heart failure (e.g., edema)
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Lower Extremity Amputation Unilateral transtibial amputation Been fit with a prosthesis and used it for at least six months Wear the prosthesis for four or more ours on an average day Ambulate without upper extremity aids Able to walk for 30 minutes on a treadmill  Improper fit and suspension with current prosthesis and one cannot be achieved with clinical resources (determined at initial visit) Current skin irritation or injury on residual limb Osteoarthritis, injury, or pain that interferes with walking ability Currently incarcerated Pregnant (determined via self-report) Inadequate cognitive function or language proficiency to consent to participate High (>20%) coronary heart disease risk at 10 years as determined by heir Framingham Risk Score
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 0.083-18.0,  Kawasaki Disease Appendicitis Patients with Kawasaki disease Acute abdomen requiring surgery  Patients with chronic gastrointestinal disease Incomplete data on the charts
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Lung Injury scheduled for Laparoscopic colorectal cancer resection 2. age >65 years 3. body mass index(BMI) 18-30kg / m2 4. ASA gradingⅠ-Ⅲ  history of lung surgery 2. severe restrictive or obstructive pulmonary disease (preoperative lung function test: forced vital capacity(FVC)< 50% predictive value of FVC,forced expiratory volume at one second(FEV1)< 50% predictive value of FEV1 3. Acute respiratory failure, pulmonary infection, ALI/ARDS, and acute stage of asthmaAcute respiratory failure, pulmonary infection, acute lung injury(ALI),acute respiratory distress syndrome(ARDS), and acute stage of asthma (bronchodilators were needed for treatment) were found within 1 month before surgery 4. Patients at risk of preoperative reflux aspiration 5. Preoperative positive pressure ventilation (as obstructive sleep apnea hypopnea syndrome patients) or long-term home oxygen therapy were performed 6. Serious heart, liver and kidney diseases: heart function class more than 3, severe arrhythmia (sinus bradycardia (ventricular rate < 60 times/min), atrial fibrillation, atrial flutter, atrioventricular block, frequent premature ventricular and polyphyly ventricular early, early to R on T, ventricular fibrillation and ventricular flutter), acute coronary syndrome, liver failure, kidney failure 7. Neuromuscular diseases affect respiratory function, such as Parkinson's disease, myasthenia gravis and cerebral infarction affect normal breathing 8. Mental illness, speech impairment, hearing impairment 9. Contraindications for spinal anesthesia puncture 10. Refuse to participate in this study or participate in other studies -
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rheumatoid Arthritis Patients who diagnosed of rheumatoid arthritis as of ACR/EULAR 2010 All patients age range is 18-80 years  Renal failure Hepatic insufficiency Diabetes mellitus Other collagen vascular diseases History of smoking and consumption of alcohol